Get the Stockscreener App
3.29
0.92%
0.03
After Hours:
3.35
0.06
+1.82%
Larimar Therapeutics Inc stock is traded at $3.29, with a volume of 1.75M.
It is up +0.92% in the last 24 hours and up +3.79% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
See More
Previous Close:
$3.26
Open:
$3.29
24h Volume:
1.75M
Relative Volume:
0.87
Market Cap:
$341.77M
Revenue:
-
Net Income/Loss:
$-166.01M
P/E Ratio:
-1.5834
EPS:
-2.0778
Net Cash Flow:
$-131.32M
1W Performance:
+2.81%
1M Performance:
+3.79%
6M Performance:
-2.37%
1Y Performance:
+2.81%
1-Day Range:
$3.26
$3.375
1-Week Range:
$2.96
$3.385
52-Week Range:
$2.715
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.29 | 316.84M | 0 | -166.01M | -131.32M | -2.0778 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's AtaxiaSlideshow (NASDAQ:LRMR) 2026-07-01 - Seeking Alpha
Enterprise value to EBIT forward of Larimar Therapeutics, Inc. – LS:A2P5PP - TradingView
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
LRMR Maintains by Baird -- Price Target Lowered to $5.00 - GuruFocus
A Quick Look at Today's Ratings for Larimar Therapeutics(LRMR.US), With a Forecast Between $5 to $25 - Moomoo
Larimar Therapeutics: Late-Stage FA Program Advances Amid Execution Risks (NASDAQ:LRMR) - Seeking Alpha
Larimar Therapeutics submits rolling BLA for nomlabofusp - The Pharma Letter
Buy Recommendation for Larimar Therapeutics (LRMR) Following Mar - GuruFocus
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Larimar Therapeutics (LRMR) Faces Stock Decline After Safety Fin - GuruFocus
LRMR Stock Dips As Traders Weigh Cash Runway And Volatility - StocksToTrade
Larimar Therapeutics submits first module of rolling BLA for nomlabofusp in Friedreich’s ataxia - grafa.com
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug - Benzinga
LRMR Stock Slides As Traders Eye Cash Runway And Volatility - StocksToTrade
Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR) - Yahoo Finance
Larimar submits first module of rolling BLA for nomlabofusp - Investing.com UK
LRMR Stock Holds Support As Biotech Traders Watch Cash Runway - timothysykes.com
Why is Larimar Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Why is Larimar Therapeutics stock sliding today? - Investing.com
Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Microcap Growth Benchmark Index - marketscreener.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Larimar Therapeutics stock tumbles after clinical data release - Investing.com
Larimar Therapeutics Submits First Module of Rolling Bla and Reports Positive Open Label Data for Nomlabofusp in Friedreich?S Ataxia - marketscreener.com
Larimar Therapeutics (LRMR) Submits First Module for Accelerated Approval - GuruFocus
Larimar Advances Nomlabofusp BLA Toward Accelerated Approval - TipRanks
Larimar submits first module of rolling BLA for nomlabofusp By Investing.com - Investing.com South Africa
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 2000 Growth Benchmark - marketscreener.com
LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and strong regulatory progress - TradingView
Larimar Therapeutics submits first module of rolling BLA after positive nomlabofusp open‑label data - TradingView
LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and advances toward accelerated approval - TradingView
Larimar Therapeutics Reports Positive Open Label Data and - GlobeNewswire
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 3000E Growth Benchmark - marketscreener.com
Larimar Therapeutics to host investor event on Monday By Investing.com - Investing.com South Africa
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia - The Manila Times
Larimar to discuss Friedreich’s ataxia drug data June 29 - Stock Titan
Larimar Therapeutics Up Nearly 32%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk - Moomoo
Larimar Therapeutics, Inc. Actuals & Estimates (NASDAQ:LRMR) - TradingView
LRMR Forecast — Price Target — Prediction for 2027 - TradingView
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Larimar Therapeutics Inc (LRMR) Institutional Confidence - TradingKey
What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter - Kavout | AI
Larimar Therapeutics Inc (LRMR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Larimar Therapeutics Inc (LRMR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Larimar Therapeutics Inc (LRMR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Larimar Therapeutics Inc (LRMR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Larimar Therapeutics Inc Stock (LRMR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hamilton Thomas Edward | Director |
Feb 27 '26 |
Buy |
5.00 |
100,000 |
500,000 |
664,798 |
| THOMAS FRANK E | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
7,000 |
| SHERMAN JEFFREY W | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
5,000 |
| Flynn James E | Director |
Jul 31 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
9,538,945 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):